钙硅生物陶瓷骨修复材料骨修复效果研究

注册号:

Registration number:

ChiCTR2500103668 

最近更新日期:

Date of Last Refreshed on:

2025-06-03 17:00:31 

注册时间:

Date of Registration:

2025-06-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

钙硅生物陶瓷骨修复材料骨修复效果研究

Public title:

Research on the Bone Repair Effect of Calcium-Silicon Bioceramic Bone Repair Materials

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探索钙硅生物陶瓷骨修复材料用于经侧壁开窗上颌窦提升术中的骨修复效果研究

Scientific title:

To explore the bone repair effect of calcium-silicon bioceramic bone repair materials in maxillary sinus elevation through lateral fenestration

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

伊哲 

研究负责人:

伊哲 

Applicant:

Zhe Yi 

Study leader:

Zhe Yi 

申请注册联系人电话:

Applicant telephone:

+86 18040229988

研究负责人电话:

Study leader's
telephone:

+86 24 31927710

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zheyi@cmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

zheyi@cmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市和平区南京北街117号

研究负责人通讯地址:

辽宁省沈阳市和平区南京北街117号

Applicant address:

No. 117, Nanjing North Street, Heping District, Shenyang City, Liaoning Province

Study leader's address:

117 Nanjing North Street, Heping District, Shenyang, Liaoning, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属口腔医院

Applicant's institution:

Affiliated Stomatological Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属口腔医院

Affiliation of the Leader:

Medical Ethics Committee of China Medical University and Stomatology Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

中国医科大学附属口腔医院(2025)伦审字(1)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属口腔医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of China Medical University andStomatology Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-04-14 00:00:00

伦理委员会联系人:

曲健

Contact Name of the ethic committee:

Qu Jian

伦理委员会联系地址:

辽宁省沈阳市和平区南京北街117号

Contact Address of the ethic committee:

117 Nanjing North Street, Heping District, Shenyang, Liaoning, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 24 3192 7812

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1658359787@163.com

研究实施负责(组长)单位:

中国医科大学附属口腔医院

Primary sponsor:

Medical Ethics Committee of China Medical University and Stomatology Hospital

研究实施负责(组长)单位地址:

沈阳市和平区南京北街117号

Primary sponsor's address:

117 Nanjing North Street, Heping District, Shenyang, Liaoning, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属口腔医院

具体地址:

沈阳市和平区南京北街117号

Institution
hospital:

Medical Ethics Committee of China Medical University and Stomatology Hospital

Address:

117 Nanjing North Street, Heping District, Shenyang, Liaoning, China

经费或物资来源:

烟台正海生物科技股份有限公司

Source(s) of funding:

Yantai Zhenghai Biotechnology Co., Ltd.

研究疾病:

口腔种植牙槽骨骨量不足  

Target disease:

Insufficient bone mass in dental implant alveolar bone

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

探索钙硅生物陶瓷骨修复材料用于经侧壁开窗上颌窦提升术中的骨修复效果。  

Objectives of Study:

To explore the bone repair effect of calcium-silicon bioceramic bone repair materials in maxillary sinus floor elevation via lateral window approach.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1) 手术牙位既往填充过骨粉的患者;
2) 存在上颌窦急性感染、上颌窦囊肿的患者;
3) 未经治疗的牙周炎患者,急性根尖周炎、根尖周囊肿和/或中晚期牙周病的患者;
4) 口腔环境较差,不能保持良好的口腔卫生护理的患者;
5) 有头颈部放疗史的患者;
6) 控制不良的糖尿病(糖化血红蛋白(HbA1c)>7.5%),控制不良的高血压(收缩压≥160 mmHg 和/或舒张压≥100 mmHg)患者;
7) 肝肾功能异常(ALT 和AST 值超过正常值上限的1.5 倍,或肌酐超过正常值)的患者;
8) 患有骨代谢性疾病(如:骨质疏松、畸形性骨炎等),或入组前3 个月内服用过可显著影响骨代谢的药物或制品(如类固醇,二膦酸盐等 )的患者;
9) 有严重心、肝、肺、肾等重要脏器疾病或严重血液、免疫、内分泌系统疾病的患者;
10) 大量吸烟(≥10支/天)的患者;
11) 妊娠及意向妊娠的育龄期妇女或哺乳期妇女;配偶有妊娠意向的男性患者;
12) 严重精神疾病患者;
13) 患者近3个月内参加过或正在参加其他药物或器械临床试验;
14) 依从性差或其他经研究者判定不适合纳入的患者;

Exclusion criteria:

1)Patients with a history of bone grafting in the surgical tooth site; 2)Patients with acute maxillary sinus infection or maxillary sinus cysts; 3)Patients with untreated periodontitis, acute periapical periodontitis, periapical cysts, and/or moderate to advanced periodontal disease; 4)Patients with poor oral hygiene or inability to maintain good oral care; 5)Patients with a history of head and neck radiotherapy; 6)Patients with poorly controlled diabetes (glycated hemoglobin [HbA1c] >7.5%) or poorly controlled hypertension (systolic blood pressure >=160 mmHg and/or diastolic blood pressure >=100 mmHg); 7)Patients with abnormal liver or kidney function (ALT and AST values exceeding 1.5 times the upper limit of normal, or creatinine exceeding normal values); 8)Patients with bone metabolic diseases (e.g., osteoporosis, Paget's disease of bone, etc.) or those who have taken medications or products significantly affecting bone metabolism (e.g., steroids, bisphosphonates, etc.) within 3 months prior to enrollment; 9)Patients with severe diseases of vital organs (heart, liver, lung, kidney, etc.) or severe hematological, immune, or endocrine system diseases; 10)Patients with heavy smoking history (>=10 cigarettes/day); 11)Pregnant women, women of childbearing age intending to become pregnant, or lactating women; male patients whose spouses have pregnancy intentions; 12)Patients with severe mental illnesses; 13)Patients who have participated in or are currently participating in other drug or medical device clinical trials within the past 3 months; 14)Patients with poor compliance or other conditions deemed unsuitable for enrollment by the investigator.

研究实施时间:

Study execute time:

From 2025-05-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-16 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

7

Group:

Experimental group

Sample size:

干预措施:

使用钙硅生物陶瓷骨修复材料进行经侧壁开窗上颌窦提升术,术中同期植入种植体

干预措施代码:

Intervention:

The lateral window approach for maxillary sinus floor elevation is performed using calcium-silicon bioceramic bone repair materials, with simultaneous

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Medical Ethics Committee of China Medical University and Stomatology Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

有效性指标

指标类型:

主要指标

Outcome:

Efficacy indicators

Type:

Primary indicator

测量时间点:

术后即刻及术后180天±14天

测量方法:

分别于术后即刻及术后180天±14天拍摄CBCT,通过阅片软件测量后评估术后180天±14天与术后即刻相比牙槽嵴高度的变化情况。

Measure time point of outcome:

Immediately after surgery and at 180 days +/-14 days postoperatively

Measure method:

CBCT scans will be taken immediately after surgery and at 180 days ±14 days postoperatively. The change in alveolar ridge height between 180 days ±14 days postoperatively and immediately after surgery will be evaluated by measuring through film-reading software.

指标中文名:

安全性指标

指标类型:

次要指标

Outcome:

Safety indicators

Type:

Secondary indicator

测量时间点:

术后14 天±3 天、30 天±3 天、180 天±14 天

测量方法:

评价术后14 天±3 天、30 天±3 天、180 天±14 天受试者材料植入区的牙龈组织的伤口愈合情况。

Measure time point of outcome:

14 days +/- 3 days, 30 days +/-3 days, and 180 days +/-14 days after surgery

Measure method:

Evaluate the wound healing status of the gingival tissue in the material implantation area of the subjects at 14 days ± 3 days, 30 days ± 3 days, and 180 days ± 14 days postoperatively.

指标中文名:

安全性指标

指标类型:

次要指标

Outcome:

Safety indicators

Type:

Secondary indicator

测量时间点:

术后

测量方法:

记录窦膜穿孔、上颌窦炎、术后感染、术后出血、鼻出血、鼻塞、血肿等并发症发生情况

Measure time point of outcome:

Postoperative

Measure method:

Record the occurrence of complications such as sinus membrane perforation, maxillary sinusitis, postoperative infection, postoperative bleeding, epistaxis, nasal obstruction, and hematoma.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-06-03 16:59:44